Comparative Study to Evaluate Safety and Efficacy of Sitagliptin Versus Metformin Alone and Combination in Type 2 Diabetes Mellitus
Naveed Altaf, Mirza Arshad Asif Baig · EAS Journal of Pharmacy and Pharmacology · 2021
Introduction: Type 2 Diabetes mellitus is characterized by high blood glucose, insulin resistance, and relative lack of insulin.Common symptoms include increased thirst, frequent urination, and unexplained weight loss.Material and Methods: This is a Prospective, Comparative, Randomized and Parallel group study.Study was conducted in Type 2DM patients attending the outpatient department of Medicine in tertiary care center.Group I received Metformin 500 mg BD for 3 months, Group II received Sitagliptin 50 mg BD for 3 months and Group III Metformin 500 mg BD and Sitagliptin 50mg BD for 3 months.Result: The mean fasting blood glucose level in Group I at baseline was 143.14±5.38 mg/dl and after 3 months was 93.85 mg/dl, in Group II was 147.15 ±5.38 mg/dl and after 3 months 91.47±4.20 mg/dl and in Group III was 145.23±5.47mg/dl and after 3 months 87.47±4.27mg/dl.The mean of PPBG level in Group I was 194.23±14.58mg/dl at baseline, followed by 152.68±9.24mg/dl after 3 rd month.In Group II the mean of PPBG level was 197.79±14.52mg/dl at baseline followed by 131.47±8.63mg/dl after 3 rd month.In Group III the mean of PPBG level was 196.64±13.63mg/dl at baseline followed by 127.74±9.37 mg/dl after 3 rd month.Conclusion: Both sitagliptin or metformin monotherapy helped in improving glycemic control in patients with type 2 diabetes mellitus.Both the group of the drugs was well tolerated by the patients.The result of this study provides the data for the use of sitagliptin as initial monotherapy for type 2 diabetes mellitus patients.